SIX1's unfavorable impact on clinical outcome of luminal group was supported by Iwanaga R’ research.[13] Apart from these, higher SIX3 mRNA level was strikingly found to contribute to a better OS and RFS in basal-like breast cancer population, indicating that SIX3 is an anticancer factor for basal-like breast tumor. This evidence concerns the gene SIX3 and breast cancer.